How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review
Authors:
- Iris ParriniIPIris Parrini
- Fabiana LucàFLFabiana Lucà
- Carmelo Massimiliano RaoCRCarmelo Massimiliano Rao
- Stefano CacciatoreSCStefano Cacciatore
- Carmine RiccioCRCarmine Riccio
- Massimo GrimaldiMGMassimo Grimaldi
- Michele Massimo GuliziaMGMichele Massimo Gulizia
- Fabrizio OlivaFOFabrizio Oliva
- Felicita AndreottiFAFelicita Andreotti
Open Access
- 5 April 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 2119
Abstract
Beta blockers (BBs) play a crucial role in enhancing the quality of life and extending the survival of patients with heart failure and reduced ejection fraction (HFrEF). Initiating the therapy at low doses and gradually titrating the dose upwards is recommended to ensure therapeutic efficacy while mitigating potential adverse effects. Vigilant monitoring for signs of drug intolerance is necessary, with dose adjustments as required. The management of older HF patients requires a case-centered approach, taking into account individual comorbidities, functional status, and frailty. Older adults, however, are often underrepresented in randomized clinical trials, leading to some uncertainty in management strategies as patients with HF in clinical practice are older than those enrolled in trials. The present article performs a scoping review of the past 25 years of published literature on BBs in older HF patients, focusing on age, outcomes, and tolerability. Twelve studies (eight randomized-controlled and four observational) encompassing 26,426 patients were reviewed. The results indicate that BBs represent a viable treatment for older HFrEF patients, offering benefits in symptom management, cardiac function, and overall outcomes. Their role in HF with preserved EF, however, remains uncertain. Further research is warranted to refine treatment strategies and address specific aspects in older adults, including proper dosing, therapeutic adherence, and tolerability.Keywords
This publication has 84 references indexed in Scilit:
- Heart Failure With Preserved Ejection FractionJAMA, 2023
- Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence mapEuropean Journal of Heart Failure, 2021
- Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan PolicyJAMA Internal Medicine, 2020
- Sex- and Age-Related Differences in the Management and Outcomes of Chronic Heart Failure: An Analysis of Patients from the ESC HFA EORP Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2019
- Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection FractionJAMA Network Open, 2019
- Association Between Beta-Blocker Use and Mortality/Morbidity in Older Patients with Heart Failure with Reduced Ejection Fraction. A Propensity Score-Matched Analysis from the Swedish Heart Failure RegistryEuropean Journal of Heart Failure, 2019
- Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fractionCochrane Database of Systematic Reviews, 2018
- Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial InfarctionJAMA Internal Medicine, 2017
- Trends in Prevalence from 1990 to 2007 of Patients Hospitalized with Heart Failure in SwedenEuropean Journal of Heart Failure, 2014
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000